Gsa Capital Partners LLP Myovant Sciences Ltd. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$11.38 - $16.4 $211,508 - $304,810	-18,586 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$14.31 - $23.87 $61,962 - $103,357	4,330 Added 30.37%	18,586 $289,000
Q3 2021 Nov 12, 2021	BUY	$18.94 - $26.99 $60,683 - $86,475	3,204 Added 28.99%	14,256 $320,000
Q2 2021 Aug 05, 2021	BUY	$17.07 - $24.56 $188,657 - $271,437	11,052 New	11,052 $252,000
Q1 2021 May 10, 2021	SELL	$20.46 - $25.18 $246,624 - $303,519	-12,054 Closed	0 $0
Q4 2020 Feb 03, 2021	SELL	$13.8 - $27.62 $31,243 - $62,531	-2,264 Reduced 15.81%	12,054 $333,000
Q3 2020 Nov 06, 2020	BUY	$14.05 - $22.6 $201,167 - $323,586	14,318 New	14,318 $201,000
Q4 2019 Feb 12, 2020	SELL	$4.2 - $19.21 $107,877 - $493,408	-25,685 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$5.19 - $9.46 $133,305 - $242,980	25,685 New	25,685 $134,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.